PODD ALERT: Levi & Korsinsky Investigates Insulet Corporation on Behalf of Shareholders Who Lost Money Ready to Announce with Confidence?
New York, New York--(Newsfile Corp. - April 6, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Insulet Corporation (NASDAQ: PODD) ("Insulet Corporation") concerning potential violations of the federal securities laws.
During that same February 18 earnings call, McEvoy stated that "strong clinical evidence and real-world outcomes continue to earn prescriber and patient confidence" and described Omnipod 5 as the "favorite pump" for both type-1 and type-2 users in 2025. CFO Flavia Pease added that U.S. revenue growth was "above the high end of our guidance range, driven by continued demand for Omnipod 5 across type 1 and type 2 customers." At no point during the call did any executive reference a product-quality issue, a pending regulatory action, or an anticipated recall.
Only a few weeks later, the March 12 filing revealed a defect affecting Omnipod 5 Pods. The filing identified insulin leakage capable of causing diabetic ketoacidosis -- a serious medical emergency. The Company's February 18 statements about Omnipod reliability, patient confidence, and demand-driven growth had not referenced any of these issues.
If you suffered a loss on your Insulet Corporation securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/291257
Source: Levi & Korsinsky, LLP
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Levi & Korsinsky, LLP or all companies in the Banking / Financial Services industry.
PODD ALERT: Levi & Korsinsky Investigates Insulet Corporation on Behalf of Shareholders Who Lost Money
2026-04-06 12:42 AM EDT
Investors in Disc Medicine, Inc. (IRON) Warned of Potential Securities Fraud - Contact Levi & Korsinsky Today
2026-04-06 12:39 AM EDT
Investigation Opened on Behalf of ADMA Biologics, Inc. (ADMA) Shareholders - Contact Levi & Korsinsky
2026-04-06 12:36 AM EDT
Jul 29, 2025
Here’s what we’ve learned from over 200,000 regulatory filings—and how you can apply it: For the 200+ Canadian companies also listed in the United States, the stakes for regulatory compliance have never been higher. A single filing error can trigger significant stock price volatility and lead to major financial and reputational damage. SEDAR+ and EDGAR process thousands of filings every day. In just its first three months, SEDAR+ handled over 30,000 disclosures. EDGAR, meanwhile, processes...
Economy, Business and Finance
Legal Service
Litigation and Regulation
Banking / Financial Services